Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
YMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.25 - $17.78
Previous CloseN/A
Volume43.26K
Average Volume (3M)486.90K
Market Cap
$223.38M
Enterprise Value$519.80M
Total Cash (Recent Filing)$78.64M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 12, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,218,178
10 Day Avg. Volume431,252
30 Day Avg. Volume486,897
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.45
Price to Cash Flow (P/CF)-28.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.15
Enterprise Value/Ebitda-18.65
Forecast
1Y Price Target
$17.70Price Target Upside258.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Global ExpansionDanyelza revenues are expected to continue to grow as the company continues outreach in the US and globally.
Research And DevelopmentAnalyst has strong conviction in the potential of the company's pretargeting radiopharmaceutical platform to deliver high quality, differentiated assets.
Bears Say
Revenue GuidanceFlat to down FY25 revenue guidance of $75M - $90M triggered a negative stock reaction.
---
Ownership Overview
23.86% Insiders
7.72% Mutual Funds
<0.01% Other Institutional Investors
57.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $4.25 and its highest was $17.78 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Y-Mabs Therapeutics’s market cap is $223.38M.
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 60 days.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on Mar 04, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.116 by -$0.034.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 45,218,178 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.116. Following the earnings report the stock price went down -4.432%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Currently, no hedge funds are holding shares in YMAB
---
Y-Mabs Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.70 (258.30% Upside)
$17.70 (258.30% Upside)
Blogger Sentiment
Bearish
YMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 17.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $76.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 12.7%
Last 30 Days ▼ 12.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.04%
12-Months-Change
Fundamentals
Return on Equity
-30.74%
Trailing 12-Months
Asset Growth
-6.23%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
---
YMAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive achievements, particularly in international revenue growth, radiopharmaceutical platform progress, and strong financial positioning. However, these were balanced by challenges, including revenue decline in the U.S., increased net loss, and difficulties in patient enrollment for trials. The strategic realignment is expected to address some of these challenges.Read More>---
YMAB Stock 12 Month Forecast
Average Price Target
$17.70
▲(258.30% Upside)
Technical Analysis
Best Analysts Covering YMAB
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
-8.59%
reiterated a sell rating 9 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of -8.59% per trade.
---